GBS

General Information
Business:

 

We are a biosensor diagnostic technology company operating in the APAC Region. Our objective is to introduce and launch the Saliva Glucose Biosensor (referred to as the “SGB”), the first of our diagnostic tests that stem from the Biosensor Platform that we license, in the APAC Region. The SGB uses saliva to measure glucose non-invasively. When the SGB interacts with saliva, an electrochemical reaction is initiated that produces an electrical signal directly correlated to the amount of glucose present in the saliva. This measurement is then converted into a real-time saliva glucose reading by a software app on a smart device or a dedicated smart reader for those that do not possess a compliant and compatible smart device. The reading may then be stored in our proprietary cloud-based digital information system.

 

Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees: 11
Founded: 2016
Contact Information
Address 708 Third Avenue, 6th Floor, New York, NY 10017, US
Phone Number (646) 828-8258
Web Address
View Prospectus: GBS
Financial Information
Market Cap
Revenues $0.2 mil (last 12 months)
Net Income $-6.15 mil (last 12 months)
IPO Profile
Symbol GBSG
Exchange TBA
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $23.0 mil
Manager / Joint Managers Aegis Capital
CO-Managers -
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change